– Generated Record Net Revenue of $123.5 Million –

– BDSI Integration Complete; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million –

– Raises Full Year Adjusted EBITDA Guidance –

– Conference Call Scheduled for Today at 4:30 p.m. ET –

STOUGHTON, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update.

“Following closing of the financially transformative acquisition of BDSI, the Collegium team successfully completed phase one, Seamless Integration, of our three-phase action agenda, effectively transitioning operations and achieving day-one commercial readiness. We remain on track to exceed targeted run rate synergies of at least $75 million,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “In July, we transitioned to phase two, Generate Momentum, and are focused on growing Belbuca® and Xtampza® ER prescriptions, and successfully renegotiating Xtampza ER contracts that will ensure gross-to-net of less than 65% beginning in January 2023. Phase three, Accelerate, begins in January 2023, and will be propelled by Xtampza ER revenue growth and Belbuca and Xtampza ER prescription growth, and bolstered by a fully synergized cost structure.”

“In the second quarter, our first full quarter post the BDSI acquisition, we delivered record revenue, leveraged our cost structure, generated significant operating cashflows, and paid down debt,” said Colleen Tupper, Chief Financial Officer of Collegium. “Our financial position is strong, and we remain focused on strategically deploying our capital to create value for our shareholders.”

First Half 2022 Business Highlights

Financial Guidance for 2022

 PriorUpdated
   
Total Product Revenues$450.0 to $465.0 millionReaffirmed
   
Total Adjusted Operating Expenses
(Excluding Stock-Based Compensation and Acquisition Related Expenses)		$130.0 to $140.0 million$125.0 to $135.0 million
   
Total Adjusted EBITDA
(Excluding Stock-Based Compensation and Acquisition Related Expenses)		$235.0 to $250.0 million$245.0 to $255.0 million
   

Financial Results for Quarter Ended June 30, 2022

Conference Call Information 

The Company will host a conference call and live audio webcast on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time. To access the conference call, please dial (877) 407- 8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Q2 2022 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Non-GAAP Financial Measures

To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures such as adjusted EBITDA and adjusted operating expenses. We use these non-GAAP financial measures to understand, manage and evaluate our business as we believe they provide additional information on the performance of our business. We believe that the presentation of these non-GAAP financial measures, taken in conjunction with our results under GAAP, provide analysts, investors, lenders and other third parties insight into our view and assessment of our ongoing operating performance. In addition, we believe that the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide supplementary information that may be useful to analysts, investors, lenders, and other third parties in assessing our performance and results from period to period. We report these non-GAAP financial measures to portray the results of our operations prior to considering certain income statement elements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP.

In our quarterly and annual reports, earnings press releases and conference calls, we may discuss the following financial measures that are not calculated in accordance with GAAP, to supplement our consolidated financial statements presented on a GAAP basis.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

There are several limitations related to the use of adjusted EBITDA rather than net income, which is the nearest GAAP equivalent, such as:

Adjusted Operating Expenses

Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations.

The Company has not provided a reconciliation of its full-year 2022 guidance for adjusted EBITDA or adjusted operating expenses to the most directly comparable forward-looking GAAP measures because it is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense. These items are uncertain and depend on various factors that could have a material impact on GAAP net income and operating expenses for the guidance period.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our full-year 2022 financial guidance, including total projected product revenue, adjusted operating expenses and adjusted EBITDA, current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations. Actual results may differ materially from management’s expectations and such forward-looking statements in this press release could be affected as a result of various important factors, including risks relating to, among others: risks related to the ability to realize the anticipated benefits of our acquisition of BDSI, including the possibility that the expected benefits from the BDSI acquisition will not be realized or will not be realized within the expected time period; the risk that BDSI’s business will not be integrated successfully; unknown liabilities; risks related to future opportunities and plans for the products acquired with BDSI, including uncertainty of the expected financial performance of such products; the impact of the COVID-19 pandemic on our ability to conduct our business, reach our customers, and supply the market with our products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to obtain and maintain regulatory approval of our products and any product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product; the size of the markets for our products and product candidates, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products and product candidates; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement, opioid-related or other litigation that may be brought by or against us, including litigation with Purdue Pharma, L.P.; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Alex Dasalla
Head of Investor Relations
adasalla@collegiumpharma.com

 
Collegium Pharmaceutical, Inc.

Unaudited Selected Consolidated Balance Sheet Information
(in thousands)
       
  June 30, December 31,
     2022 2021
Cash and cash equivalents $122,722 $186,426
Accounts receivable, net  197,505  105,844
Inventory  77,769  17,394
Prepaid expenses and other current assets  11,778  5,879
Property and equipment, net  19,965  19,491
Operating lease assets  7,257  7,644
Intangible assets, net  647,299  268,723
Restricted cash  2,547  2,547
Deferred tax assets  28,571  78,042
Other noncurrent assets  67  87
Goodwill  130,094  —
Total assets $1,245,574 $692,077
       
Accounts payable and accrued expenses  46,331  33,403
Accrued rebates, returns and discounts  246,719  196,996
Term notes payable  605,686  110,019
Convertible senior notes  140,415  139,966
Operating lease liabilities  8,811  8,765
Shareholders’ equity  197,612  202,928
Total liabilities and stockholders’ equity $1,245,574 $692,077


 
Collegium Pharmaceutical, Inc.

Unaudited Condensed Statements of Operations
(in thousands, except share and per share amounts)
 
            
 Three Months Ended June 30, Six Months Ended June 30,
 2022 2021 2022 2021
Product revenues, net$123,549  $82,942  $207,300  $170,663 
Cost of product revenues           
Cost of product revenues (excluding intangible asset amortization) 33,684   15,908   50,016   31,236 
Intangible asset amortization 37,501   16,795   56,424   33,590 
Total cost of products revenues 71,185   32,703   106,440   64,826 
Gross profit 52,364   50,239   100,860   105,837 
Operating expenses           
Research and development —   3,462   3,983   6,392 
Selling, general and administrative 41,254   30,368   95,782   61,844 
Total operating expenses 41,254   33,830   99,765   68,236 
Income from operations 11,110   16,409   1,095   37,601 
Interest expense (17,761)  (5,421)  (23,592)  (11,142)
Interest income 5   3   9   6 
(Loss) income before income taxes (6,646)  10,991   (22,488)  26,465 
Benefit from income taxes (1,455)  (61,852)  (4,228)  (62,040)
Net (loss) income$(5,191) $72,843  $(18,260) $88,505 
            
(Loss) earnings per share — basic$(0.15) $2.06  $(0.54) $2.52 
Weighted-average shares — basic 34,001,553   35,302,608   33,838,638   35,128,144 
            
(Loss) earnings per share — diluted$(0.15) $1.79  $(0.54) $2.20 
Weighted-average shares — diluted 34,001,553   41,286,853   33,838,638   41,251,749 


 
Collegium Pharmaceutical, Inc.

Reconciliation of GAAP Net Income to Adjusted EBITDA
(in thousands)
(unaudited)
            
 Three Months Ended June 30, Six Months Ended June 30,
 2022 2021 2022 2021
GAAP Net (loss) income$(5,191) $72,843  $(18,260) $88,505 
Adjustments:           
Interest expense 17,761   5,421   23,592   11,142 
Interest income (5)  (3)  (9)  (6)
Benefit from income taxes (1,455)  (61,852)  (4,228)  (62,040)
Depreciation 656   425   1,371   864 
Amortization 37,501   16,795   56,424   33,590 
Stock-based compensation expense 5,692   6,516   11,827   13,395 
Acquisition related expense 3,579   —   30,746   — 
Recognition of step-up basis in inventory 12,638   —   13,241   — 
Total adjustments$76,367  $(32,698) $132,964  $(3,055)
Adjusted EBITDA$71,176  $40,145  $114,704  $85,450 


 
Collegium Pharmaceutical, Inc.

Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses
(in thousands)
(unaudited)
                
 Three Months Ended June 30, Six Months Ended June 30,
 2022 2021    2022 2021
GAAP Operating expenses$41,254  $33,830  $99,765  $68,236 
Adjustments:               
Stock-based compensation 5,692   6,516   11,827   13,395 
Acquisition related expense 3,579   —   30,746   — 
Total adjustments 9,271   6,516   42,573   13,395 
Adjusted operating expenses$31,983  $27,314  $57,192  $54,841